Search clinical trials for: TAK-137 5mg tablet, TAK-137 placebo tablet

Total 926 results

Takeda

Withdrawn

A Phase 1, Single and Multiple Dose Study of TAK-137

Healthy Japanese Adult Male

Japan
Takeda

Terminated

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

Attention-Deficit/Hyperactivity Disorder

United States
Takeda

Completed

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants

Dose Finding Study
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Healthy

United States
Takeda

Completed

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis

Japan
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Takeda

Completed

Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"

Reflux Esophagitis

Japan
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
NeuShen Therapeutics

Not yet recruiting

First-into-human Study of NS-136 in Healthy Subjects

Healthy Subjects

Australia
Janssen Research & Development, LLC

Completed

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

HIV-1

United States
Takeda

Completed

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

Essential Hypertension

Japan
Taiho Oncology, Inc.

Terminated

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

United States, United Kingdom, Austria, France
Yonsei University

Completed

K-BASKET, TAS-117, PI3K/AKT Gene Aberration

Solid Tumor, Adult

Korea, Republic of
Takeda

Completed

TAK-114 Single- and Multiple-Dose Phase 1 Study

Clinical Pharmacology

Japan
Odense University Hospital
Rigshospitalet, Denmark; Danish Cancer Society; REHPA, The Danish Knowledge Centre...

Completed

The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving Immunotherapy

Adverse Effects

Denmark
GlaxoSmithKline

Terminated

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

Infections, Bacterial

United States
Millennium Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States, Spain, United Kingdom
Center for Research on Filariasis and Other Tropical...

Active, not recruiting

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients (EOLoa)

Onchocerciasis, Ocular | Loiasis

Cameroon
Takeda

Completed

A Bioequivalence Study of TAK-536 Pediatric Formulation

Japanese Healthy Adult Males

Japan
Daewoong Pharmaceutical Co. LTD.

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Idiopathic Pulmonary Fibrosis

United States, Korea, Republic of
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Not yet recruiting

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Damanhour University

Completed

Ivabradine in Patients With Congestive Heart Failure

Congestive Heart Failure

Egypt
Bayer

Completed

Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients

Chagas Disease

Argentina
Takeda

Completed

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

Schizophrenia

United States
Daiichi Sankyo, Inc.
ICON Clinical Research; ArQule, Inc. (a wholly owned subsidiary of Merck Sharp...

Completed

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Solid Tumors

United States
Takeda

Completed

Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)

Non-erosive Gastroesophageal Reflux Disease

Japan
Virginia Polytechnic Institute and State University

Recruiting

The Role of the Locus Coeruleus in Age-related Distractibility

Alzheimer Disease | Aging

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors

Neoplasms, Advanced Solid

Netherlands
NYU Langone Health
National Institute of Mental Health (NIMH)

Withdrawn

Examine the Preliminary Effect of an Evidence-Based Practice (EBP) Consultation Model on Staff Fidelity to EBP

Stress Disorders, Post-Traumatic
Eidos Therapeutics, a BridgeBio company
Celerion

Completed

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

Amyloid Cardiomyopathy, Transthyretin-Related

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
Bausch Health Americas, Inc.

Completed

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Liver Cirrhosis

United States, Russian Federation
Takeda

Completed

Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"

A History of Gastric or Duodenal Ulcers

Japan
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
Millennium Pharmaceuticals, Inc.

Completed

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Metastatic Solid Tumors

United States, Spain, United Kingdom
Biota Pharmaceuticals, Inc.

Completed

A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers

Healthy

United States
University of California, Los Angeles

Recruiting

Metformin Treatment in Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
NYU Langone Health

Completed

Impact of Estrogen on Fear Extinction R61

Fear | Fear; Examination, Phobic

United States
Aviragen Therapeutics

Completed

A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

Healthy

United States
University Hospital, Basel, Switzerland

Completed

Oral Glucosestimulation After Gastric Bypass Surgery

Obesity

Switzerland
Taiho Oncology, Inc.

Completed

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Advanced Solid Tumors (Excluding Breast Cancer)

United States
University of Michigan
Food and Drug Administration (FDA)

Recruiting

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers

Human Gastrointestinal Physiology Data

United States
Cephalon
H. Lundbeck A/S; The Parkinson Study Group

Terminated

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

Parkinson Disease

United States, Canada, Puerto Rico
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition

Healthy

Indonesia

3

Subscribe